BioNTech (BNTX) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic vision and achievements

• Advanced oncology portfolio into late-stage development, with 15 ongoing phase II and III trials, including pivotal studies for BNT327 targeting SCLC, TNBC, and NSCLC.

• Maintained global leadership in COVID-19 vaccines, holding over 50% market share and strengthening financial position, with approximately €17.4 billion in cash and investments as of December 31, 2024.

• Acquired or planned acquisition of Biotheus to gain global control of BNT327 and enhance immunotherapy capabilities, with the deal expected to close in Q1 2025.

• Built unique capabilities in genomics, immunology, AI-driven drug discovery, and automated mRNA manufacturing for personalized precision medicines.

• Developed a broad portfolio of immune modulators, mRNA immunotherapies, and targeted therapies, leveraging AI for drug design and optimization.

Oncology pipeline and clinical progress

• Focused on two high-priority pan-tumor programs: mRNA immunotherapies (FixVac, iNeST) and bispecific antibody BNT327, with BNT327 highlighted as a next-generation IO-backbone.

• BNT327 demonstrated high clinical potential across over 750 patients, with encouraging response rates and disease control in multiple cancers, including efficacy in TNBC regardless of PD-L1 status.

• Initiated 20 clinical trials for BNT327, including registrational studies in TNBC and lung cancers, and accelerating global clinical development for BNT3271.

• Strategy includes three waves of registration trials: replacing standard of care, combining with ADCs, and exploring further combinations, aiming to address over 1.4 million new cancer cases annually in the US and EU not covered by current IO therapies.

• Data readouts for BNT3271 expected in 2025 across several indications and combinations.

mRNA immunotherapy platforms and clinical data

• Developed iNeST (individualized neoantigen-specific) and FixVac (shared antigen) mRNA vaccine platforms, using AI for target selection and treating over 450 patients with 18,000 neoantigens selected.

• Phase I data in over 200 patients showed robust T-cell responses, both amplifying existing and generating new neoantigen-specific T-cells.

• Early trials in pancreatic and colorectal cancer adjuvant settings indicate strong immune responses correlate with reduced relapse.

• Ongoing phase II trials in ctDNA-positive colorectal cancer and MIUC patients use personalized vaccines to induce durable memory T-cell responses.

• Multiple randomized phase II data readouts and registration-enabling trials expected in 2025–2026, with potential for accelerated approval discussions if strong signals observed.